Recent News

Dynavax Announces Webcast of R&D Day

December 9, 2014

Dynavax and AstraZeneca to Advance TLR9 Agonist for Treatment of Asthma Into Phase 2a Clinical Study

December 8, 2014

Dynavax Regains Full Rights to Investigational TLR 7/9 Inhibitor DV1179 Following Expiration of Collaboration With GSK

November 28, 2014

Dynavax Announces Independent DSMB Recommendation to Continue Phase 3 Study of HEPLISAV-B(TM)
November 10, 2014

Dynavax Announces One-for-Ten Reverse Stock Split
November 7, 2014

Dynavax Reports Third Quarter 2014 Financial Results

November 5, 2014

Dynavax Initiates Phase 1/2 Study of TLR-9 Agonist Immunotherapy in B-Cell Lymphoma

October 13, 2014



Clinical-Stage Pipeline

Our clinical-stage pipeline includes product candidates for the prevention and treatment of infectious diseases. More...

Focused on Infectious Diseases

Scientific expertise and proprietary technologies drive our discovery and development of novel Toll-like Receptor (TLR) based product candidates. Our focus is on serious medical needs in the prevention and treatment of infectious and inflammatory diseases and cancer.  

Leading Partners

Our partnerships with leading pharmaceutical companies, including GlaxoSmithKline and AstraZeneca, and our funding agreements support our commitment to discover and develop TLR-based products to address serious medical needs.

Integrated European Subsidiary

Rhein Biotech, our European subsidiary, manufactures hepatitis B surface antigen for our lead product, HEPLISAV hepatitis B vaccine. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.